Patient characteristics
. | . | 1-locus mismatch . | . | . | |
|---|---|---|---|---|---|
. | Match . | Class I . | Class II . | 2-or 3-loci mismatch . | |
| n | 2805 | 70 | 42 | 30 | |
| Donor, n (%) | |||||
| Sibling | 2736 (98) | 39 (56) | 28 (67) | 9 (30) | |
| Others | 69 (2) | 31 (44) | 14 (33) | 21 (70) | |
| Sex, n (%) | |||||
| Male | 1711 (61) | 42 (60) | 21 (50) | 17 (57) | |
| Female | 1094 (39) | 28 (40) | 21 (50) | 13 (43) | |
| Age, n (%) | |||||
| Younger than 40 y | 1742 (62) | 45 (64) | 22 (52) | 14 (47) | |
| 40 y and older | 1063 (38) | 25 (36) | 20 (48) | 16 (53) | |
| Diagnosis, n (%) | |||||
| AML | 962 (34) | 21 (30) | 15 (36) | 10 (33) | |
| ALL | 672 (24) | 15 (21) | 13 (31) | 7 (23) | |
| CML | 804 (29) | 22 (31) | 11 (26) | 12 (40) | |
| MDS | 367 (13) | 12 (17) | 3 (7) | 1 (3) | |
| Disease risk, n (%) | |||||
| Standard | 2093 (75) | 41 (59) | 26 (62) | 7 (23) | |
| High | 712 (25) | 29 (41) | 16 (38) | 23 (77) | |
| Conditioning regimen, n (%) | |||||
| Non-TBI | 1126 (40) | 19 (27) | 15 (36) | 9 (30) | |
| TBI | 1679 (60) | 51 (73) | 27 (64) | 21 (70) | |
| Use of PBSCs, n (%) | |||||
| No | 2465 (88) | 54 (77) | 35 (83) | 14 (47) | |
| Yes | 340 (12) | 16 (23) | 7 (17) | 16 (53) | |
| Experienced engraftment failure, | |||||
| n (%) | 67 (2.4) | 6 (9) | 0 (0) | 3 (10) | |
| Number of genotype mismatches | |||||
| 0 | 2771 | 0 | 0 | 0 | |
| 1 | 3 | 22 | 20 | 0 | |
| 2 | 0 | 3 | 0 | 18 | |
| 3 | 0 | 0 | 0 | 8 | |
| ND | 31 | 45 | 22 | 4 | |
. | . | 1-locus mismatch . | . | . | |
|---|---|---|---|---|---|
. | Match . | Class I . | Class II . | 2-or 3-loci mismatch . | |
| n | 2805 | 70 | 42 | 30 | |
| Donor, n (%) | |||||
| Sibling | 2736 (98) | 39 (56) | 28 (67) | 9 (30) | |
| Others | 69 (2) | 31 (44) | 14 (33) | 21 (70) | |
| Sex, n (%) | |||||
| Male | 1711 (61) | 42 (60) | 21 (50) | 17 (57) | |
| Female | 1094 (39) | 28 (40) | 21 (50) | 13 (43) | |
| Age, n (%) | |||||
| Younger than 40 y | 1742 (62) | 45 (64) | 22 (52) | 14 (47) | |
| 40 y and older | 1063 (38) | 25 (36) | 20 (48) | 16 (53) | |
| Diagnosis, n (%) | |||||
| AML | 962 (34) | 21 (30) | 15 (36) | 10 (33) | |
| ALL | 672 (24) | 15 (21) | 13 (31) | 7 (23) | |
| CML | 804 (29) | 22 (31) | 11 (26) | 12 (40) | |
| MDS | 367 (13) | 12 (17) | 3 (7) | 1 (3) | |
| Disease risk, n (%) | |||||
| Standard | 2093 (75) | 41 (59) | 26 (62) | 7 (23) | |
| High | 712 (25) | 29 (41) | 16 (38) | 23 (77) | |
| Conditioning regimen, n (%) | |||||
| Non-TBI | 1126 (40) | 19 (27) | 15 (36) | 9 (30) | |
| TBI | 1679 (60) | 51 (73) | 27 (64) | 21 (70) | |
| Use of PBSCs, n (%) | |||||
| No | 2465 (88) | 54 (77) | 35 (83) | 14 (47) | |
| Yes | 340 (12) | 16 (23) | 7 (17) | 16 (53) | |
| Experienced engraftment failure, | |||||
| n (%) | 67 (2.4) | 6 (9) | 0 (0) | 3 (10) | |
| Number of genotype mismatches | |||||
| 0 | 2771 | 0 | 0 | 0 | |
| 1 | 3 | 22 | 20 | 0 | |
| 2 | 0 | 3 | 0 | 18 | |
| 3 | 0 | 0 | 0 | 8 | |
| ND | 31 | 45 | 22 | 4 | |
ND indicates not done (ambiguous loci).